284 related articles for article (PubMed ID: 33833512)
1. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
[TBL] [Abstract][Full Text] [Related]
2. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
3. Innovative gelatin-based micelles with AS1411 aptamer targeting and reduction responsiveness for doxorubicin delivery in tumor therapy.
Yu J; Zhang Y; Xu M; Jiang D; Liu W; Jin H; Chen P; Xu J; Zhang L
Biomed Pharmacother; 2024 May; 174():116446. PubMed ID: 38513599
[TBL] [Abstract][Full Text] [Related]
4. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
Esawi E; Alshaer W; Mahmoud IS; Alqudah DA; Azab B; Awidi A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884745
[TBL] [Abstract][Full Text] [Related]
6. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
[TBL] [Abstract][Full Text] [Related]
7. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy and cardioprotection of nucleolin-targeted doxorubicin-loaded ultrasound nanobubbles in treating triple-negative breast cancer.
Fang K; Wang L; Huang H; Dong S; Guo Y
Nanotechnology; 2021 Mar; 32(24):. PubMed ID: 33690196
[TBL] [Abstract][Full Text] [Related]
9. Targeted co-delivery of FOXM1 aptamer and DOX by nucleolin aptamer-functionalized pH-responsive biocompatible nanodelivery system to enhance therapeutic efficacy against breast cancer: in vitro and in vivo.
Masoudi M; Taghdisi SM; Hashemitabar G; Abnous K
Drug Deliv Transl Res; 2024 Jun; 14(6):1535-1550. PubMed ID: 38161196
[TBL] [Abstract][Full Text] [Related]
10. NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors.
Del Valle AC; Su CK; Sun YC; Huang YF
Biomater Sci; 2020 Mar; 8(7):1934-1950. PubMed ID: 32039412
[TBL] [Abstract][Full Text] [Related]
11. Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion.
Yang S; Ren Z; Chen M; Wang Y; You B; Chen W; Qu C; Liu Y; Zhang X
Mol Pharm; 2018 Jan; 15(1):314-325. PubMed ID: 29250957
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
13. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of multimodal polymersomes for targeted drug delivery and MR/fluorescence imaging in metastatic breast cancer model.
Zavvar T; Babaei M; Abnous K; Taghdisi SM; Nekooei S; Ramezani M; Alibolandi M
Int J Pharm; 2020 Mar; 578():119091. PubMed ID: 32007591
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional hybrid micelles with tunable active targeting and acid/phosphatase-stimulated drug release for enhanced tumor suppression.
Liu X; Li Y; Tan X; Rao R; Ren Y; Liu L; Yang X; Liu W
Biomaterials; 2018 Mar; 157():136-148. PubMed ID: 29268144
[TBL] [Abstract][Full Text] [Related]
16. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
17. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
18. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases.
Zhang G; Huang X; Xiu H; Sun Y; Chen J; Cheng G; Song Z; Peng Y; Shen Y; Wang J; Cai Z
J Extracell Vesicles; 2020 Dec; 10(2):e12030. PubMed ID: 33335695
[TBL] [Abstract][Full Text] [Related]
20. A novel theranostic system of AS1411 aptamer-functionalized albumin nanoparticles loaded on iron oxide and gold nanoparticles for doxorubicin delivery.
Baneshi M; Dadfarnia S; Shabani AMH; Sabbagh SK; Haghgoo S; Bardania H
Int J Pharm; 2019 Jun; 564():145-152. PubMed ID: 30978484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
